[Brainlife] Newsletter, Vol.4 Suppl.8, 3 Jun 2005

top

BRAINLIFE NEWSLETTER

Volume 4, Supplement 8 - 3 June 2005	Volume 4 Archive

2005 ASCO Annual Meeting - Neuro-Oncology Abstracts 2005 ASCO Annual Meeting. Orlando, FL. May 13-17 - http://meeting.jco.org/content/vol23/16_suppl/

CNS Tumors
	J. P. Knisely, B. A. Berkey, A. Chakravarti, W. A. Yung, W. J. Curran, H. I. Robins, B. Movsas, D. G. Brachman, R. H. Henderson, M. P. Mehta RTOG 0118: A Phase III Study of Conventional Radiation Therapy Alone vs. Conventional Radiation Therapy Plus Thalidomide for Multiple Brain Metastases 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1500. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1500
	L. S. Ashby, J. K. Pueschel, A. C. Scheck, S. W. Coons, W. R. Shapiro Prognostic factors for patients with newly diagnosed low-grade oligodendroglial tumors: molecular genetics, histopathology, and neuroimag 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1501. (Laboratory Investigation) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1501
	J. C. Buckner, K. V. Ballman, B. W. Scheithauer, R. M. Arusell, H. E. Blair, S. M. Passe, P. D. Brown, K. A. Jaeckle, E. G. Shaw, R. B. Jenkins NCCTG 94-72-53: Diagnostic and prognostic significance of 1p and 19q deletions in patients (pts) with low-grade oligodendroglioma and astrocytoma ** 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1502. (Laboratory Investigation) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1502
	M. J. van den Bent, J. Delattre, A. A. Brandes, M. J. Taphoorn, K. Hoang Xuan, H. Bernsen, M. Frenay, W. Grisold, T. Gorlia, D. Lacombe First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma ** 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1503. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1503
	H. A. Fine, L. Kim, C. Royce, D. Draper, I. Haggarty, H. Ellinzano, P. Albert, P. Kinney, L. Musib, D. Thornton Results from phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1504. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1504
	E. Galanis, J. C. Buckner, M. J. Maurer, M. Hidalgo, J. I. Kreisberg, J. Peralba, R. B. Jenkins, D. J. Walsh N997B: Phase II Trial of CCI-779 in Recurrent Glioblastoma Mutiforme (GBM): Updated Results and Correlative Laboratory Analysis 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1505. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1505
	M. Prados, S. Kunwar, F. F. Lang, Z. Ram, M. Westphal, G. Barnett, J. H. Sampson, D. Croteau, R. K. Puri, for all participating investigators Final results of Phase I/II studies of IL13-PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant glioma 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1506. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1506
	T. Cloughesy, A. Yung, J. Vrendenberg, K. Aldape, D. Eberhard, M. Prados, S. Vandenberg, B. Klencke and P. Mischel Phase II study of erlotinib in recurrent GBM: Molecular predictors of outcome 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1507. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1507
	K. V. Ballman, K. A. Jaeckle, P. D. Brown, P. J. Flynn and J. C. Buckner NCCTG N047D: Relationship between phase II endpoints of 12 month overall survival and 6 month progression-free survival for glioblastoma multiforme (GBM) phase II trials 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1508. (Clinical Investigation) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1508
	K. Carson, S. A. Grossman, J. D. Fisher and E. Shaw Prognostic factors for survival in adult patients with recurrent glioma enrolled on New Approaches to Brain Tumor Therapy (NABTT) CNS Consortium phase I and II clinical trials ** 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1509. (Clinical Investigation) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1509
	J. J. Vredenburgh, D. Reardon, G. Akabani, A. Friedman, H. Friedman, R. McLendon, J. Quinn, J. Rich, M. Zalutsky and D. Bigner Results of a phase II study of 131 Iodine-labeled anti-tenascin murine monoclonal antibody 81C6 (m81C6) administered to deliver a targeted radiation boost dose of 44 Gy to the surgically created cystic resection cavity perimeter in the treatment of patients with newly diagnosed primary and metastatic brain tumors 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1510. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1510
	R. Cardinale, M. Won, A. Choucair, M. Gillin, A. Chakravarti, C. Schultz, L. Souhami, A. Chen, H. Pham and M. Mehta A phase II trial of accelerated radiotherapy using weekly stereotactic conformal boosts for supratentorial glioblastoma multiforme. RTOG-0023 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1511. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1511
	J.-M. Simon, K. Mokhtari, C. Genestie, A. Bissery, J.-J. Mazeron and P. Jaillon Hypoxia-inducible factor 1alpha (HIF-1α) and carbonic anhydrase IX (CA 9) expressions in glioblastoma multiform to predict response to radiation therapy 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1512. (Laboratory Investigation) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1512
	S. Krishnan, P. Brown, K. Ballman, J. Fiveash, J. Uhm, C. Giannini, F. Geoffroy, L. Nabors and J. Buckner Phase I trial of erlotinib with radiation therapy (RT) in patients with glioblastoma multiforme (GBM) 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1513. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1513
	K. A. Jaeckle, K. V. Ballman, P. Schomberg, J. Uhm, B. Schiethauer, C. Giannini, S. Felton, P. Brown, B. C. Jan NCCTG N997D: Pilot trial of CPT11 during RT followed by CPT11 and BCNU in newly diagnosed glioblastoma (GBM) patients: A North Central Cancer Group (NCCTG) study 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1514. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1514
	H. S. Friedman, J. Quinn, J. Rich, J. Vredenburgh, A. Desjardins, S. Sathornsumetee, A. Salvado, Z. Nikolova, D. Bigner and D. Reardon Efficacy of imatinib mesylate plus hydroxyurea regimen in the treatment of recurrent malignant glioma: Phase II study results 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1515. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1515
	G. Dresemann Imatinib (STI 571)/ plus hydroxyurea: Safety and efficacy in pre-treated, progressive Glioblastoma Multiforme (GBM) patients (pts): An update on the initial 30 pts 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1516. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1516
	M. van den Bent, A. Brandes, M. Frenay, P. Fumoleau, R. Stupp, C. Dittrich, B. Coudert, P. Clement, D. Lacombe and E. Raymond Multicentre phase II study of imatinib mesylate in patients with recurrent anaplastic oligodendroglioma (AOD)/mixed oligoastrocytoma (MOA) and anaplastic astrocytoma (AA)/low grade astrocytoma (LGA): An EORTC New Drug Development Group (NDDG) and Brain Tumor Group (BTG) study 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1517. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1517
	R. A. Lustig, T. Mikkelesen, G. Lesser, S. Grossman, X. Ye, S. Desideri, J. Fisher, J. Wright New Approaches to Brain Tumor Therapy Consortium Pre-radiation R115777 in patients with newly diagnosed glioblastoma multiforme and residual enhancing disease 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1518. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1518
	M. D. Groves, V. Puduvalli, M. R. Gilbert, C. A. Conrad, S. Hsu, H. Colman, K. Hess, V. A. Levin and W. K. A. Yung A phase II study of temozolomide plus pegylated interferon alfa-2b for recurrent anaplastic glioma and glioblastoma multiforme 2005 ASCO Annual Meeting. Orlando, FL. May 13-17. Abstract No. 1519. (Clinical Study) Journal of Clinical Oncology, Vol 23, No 16S (June 1 Supplement), 2005: 1519